Latest stories on PRLD
Prelude Therapeutics initiated with an Overweight at JPMorgan
The Fly61 · neutralanalyst
JPMorgan initiates Prelude Therapeutics stock at Overweight on drug potential
Investing.com Analyst Ratings61 · neutralanalyst
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire55 · neutralgeneral
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
StockTitan55 · neutralgeneral
Prelude Therapeutics IND Cleared for Novel Breast Cancer Drug
TipRanks67 · bullishproduct/pr
Prelude Therapeutics Inc (PRLD) files 8-K
SEC 8-K50 · neutralgeneral
Prelude Therapeutics receives FDA clearance for PRT13722 IND application
The Fly62 · neutralgeneral
Prelude Therapeutics: A Prognosis After Year-Long Rally
Seeking Alpha56 · neutralgeneral
Prelude Therapeutics Stock Rises on Narrower 2Q Loss, Plans to Start Trial for Breast Cancer Drug
MarketWatch58 · neutralgeneral
Prelude Therapeutics Inc (PRLD) files 8-K
SEC 8-K50 · neutralgeneral
Prelude Therapeutics reports Q2 EPS (14c), consensus (19c)
The Fly38 · neutralearnings
Prelude Therapeutics GAAP EPS of -$0.14 beats by $0.06, revenue of $5.71M
Seeking Alpha63 · neutralearnings
Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Business Insider56 · neutralgeneral
H.C. Wainwright reiterates Prelude Therapeutics stock rating on Incyte development shift
Investing.com Analyst Ratings56 · neutralanalyst
Prelude Therapeutics Inc (PRLD) files 8-K
SEC 8-K50 · neutralgeneral
Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha56 · neutralgeneral
Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD)
Yahoo Finance56 · neutralanalyst